Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX4ZWK)

• Drug Name: REC-15-2739 Drug Info
• Synonyms: Upidosin; UPIDOSIN; Rec-15-2739; 152735-23-4; UNII-TXG28R7G4Y; TXG28R7G4Y; CHEMBL278865; 4H-1-Benzopyran-8-carboxamide,N-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-3-methyl-4-oxo-2-phenyl-; Upidosin [INN]; N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide; SB 216469-S; Rec 15-2739; ACMC-20n6iu; AC1L3XX2; GTPL496; SCHEMBL6638869; CTK4C7558; DTXSID70165115; Rec 15/2739; ZINC3796141; BDBM50057465; AKOS030553705; SB 216469; L000508; SB-216469; REC-15-2869; REC-15-3011; REC-22/009

Indication

Disease Entry	ICD 11	Status	REF
Prostate disease	GA91	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 148842
  CAS Number: CAS 152735-23-4
  TTD Drug ID: DMX4ZWK

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxazosin	DM9PLRH	Benign prostatic hyperplasia	GA90	Approved	[4]
Armodafinil	DMGB035	Malignant glioma	2A00.0	Approved	[5]
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[6]
Moxisylyte	DMFCLYW	Erectile dysfunction	HA01.1	Approved	[7]
Terazosin	DM3JCVS	Benign prostatic hyperplasia	GA90	Approved	[8]
Bunazosin	DM4I8O7	Glaucoma/ocular hypertension	9C61	Approved	[9]
Trimazosin	DM1QLST	Congestive heart failure	BD10	Approved	[10]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[11]
DL-017	DMM8GZT	Hypertension	BA00-BA04	Phase 1	[12]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[13]

Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[2]
NAFTOPIDIL	DMQ8R4E	Hypertension	BA00-BA04	Approved	[2]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[14]
Xatral	DMLHOA0	Benign prostatic hyperplasia	GA90	Approved	[15]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[16]
Besipirdine	DMLVNTA	Cognitive impairment	6D71	Phase 3	[17]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[11]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[13]
PMID30124346-Compound-LDT66	DMJMTNL	Benign prostatic hyperplasia	GA90	Patented	[13]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Modulator	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003537)
• [2] Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
• [3] Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther. 1996 Jun;277(3):1237-46.
• [4] The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
• [5] Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
• [6] Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
• [7] Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
• [8] Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
• [9] Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
• [10] The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
• [11] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [12] Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
• [13] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [16] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [17] Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
• [18] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.